Trade Ultragenyx Pharmaceutical Inc - RARE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.18 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 40.72 |
| Open | 41.25 |
| 1-Year Change | -6.14% |
| Day's Range | 39.95 - 41.25 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 39.95 | -0.80 | -1.96% | 40.75 | 41.36 | 39.92 |
| Jan 16, 2025 | 40.72 | -0.19 | -0.46% | 40.91 | 41.08 | 40.23 |
| Jan 15, 2025 | 40.90 | 0.69 | 1.72% | 40.21 | 43.63 | 40.21 |
| Jan 14, 2025 | 39.95 | -3.01 | -7.01% | 42.96 | 43.20 | 39.76 |
| Jan 13, 2025 | 43.14 | 2.99 | 7.45% | 40.15 | 43.17 | 40.15 |
| Jan 10, 2025 | 42.00 | -0.68 | -1.59% | 42.68 | 42.98 | 41.44 |
| Jan 8, 2025 | 43.55 | -0.71 | -1.60% | 44.26 | 44.26 | 43.22 |
| Jan 7, 2025 | 44.38 | 1.45 | 3.38% | 42.93 | 46.13 | 42.93 |
| Jan 6, 2025 | 42.59 | 1.13 | 2.73% | 41.46 | 42.82 | 40.95 |
| Jan 3, 2025 | 41.43 | 0.33 | 0.80% | 41.10 | 41.85 | 40.40 |
| Jan 2, 2025 | 41.07 | -0.82 | -1.96% | 41.89 | 42.68 | 39.99 |
| Dec 31, 2024 | 41.99 | -0.26 | -0.62% | 42.25 | 42.59 | 41.20 |
| Dec 30, 2024 | 42.18 | -0.89 | -2.07% | 43.07 | 43.07 | 41.47 |
| Dec 27, 2024 | 43.33 | 0.22 | 0.51% | 43.11 | 43.96 | 42.79 |
| Dec 26, 2024 | 43.71 | 1.08 | 2.53% | 42.63 | 43.77 | 42.63 |
| Dec 24, 2024 | 43.64 | 0.25 | 0.58% | 43.39 | 43.87 | 43.16 |
| Dec 23, 2024 | 43.79 | -0.16 | -0.36% | 43.95 | 43.99 | 42.92 |
| Dec 20, 2024 | 44.17 | 1.58 | 3.71% | 42.59 | 44.33 | 42.59 |
| Dec 19, 2024 | 43.40 | 0.54 | 1.26% | 42.86 | 43.64 | 41.35 |
| Dec 18, 2024 | 42.90 | -1.38 | -3.12% | 44.28 | 44.74 | 42.27 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Ultragenyx Company profile
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.
Equity composition
Common Stock, $0.001 Par, 01/14, Auth. 250M Shares., 29,061,871 issd,. Insiders owns approx. 19.82%.
| Industry: | Bio Therapeutic Drugs |
60 Leveroni Ct
NOVATO
CALIFORNIA 94949
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com